Sentences with phrase «cell treatment for»

An unidentified western patient receives a stem cell treatment for heart disease at a clinic in Bangkok, Thailand on Feb. 7, 2007.

As the first and only location in Southern California dedicated to stem cell treatment for animals, the groundbreaking clinic has just opened for business in Los Angeles at 11311 Ventura Blvd. in Studio City, CA 91604.

Stem Cell Treatment For Elbow Joints At the Institute of Regenerative Medicine, we have developed an advanced medical procedure to treat numerous elbow joint conditions without the need of invasive surgery.

Forbes, Robert Langreth, February 20, 2008: In progress toward a stem - cell treatment for diabetes, researchers at a small San Diego biotech company have devised a procedure for turning human embryonic stems cells into insulin - producing cells inside mice.

A team of scientists from the UNC School of Medicine and North Carolina State University (NCSU) has developed promising research towards a possible stem cell treatment for several lung conditions, such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosis — often - fatal conditions that affect tens of millions of Americans.

The challenge takes on even more urgency with recent developments, including a federal administration now more open to exploring the potential of stem cells, the recent FDA approval of a human trial involving embryonic stem cells, as well as the reported case of a young boy who developed a brain tumor four years after receiving a stem - cell treatment for a rare genetic disorder.

In this short video, cardiologist and researcher Dr. Leslie Miller gives an overview of the regenerative capabilities of stem cell treatment for heart failure.

As was recently announced, Okyanos now offers an advanced stem cell treatment for diffuse scleroderma based on the well - established protocol implemented in the STAR Clinical Trial.

Clinical translation is the obvious answer, and hopefully this research will represent an important step in reducing the risk of stem cell treatment for diabetes, as well as other diseases.

Scientists at the University of York have taken a leaf out of nature's book in an attempt to develop effective stem cell treatment for osteoarthritis, a condition which affects millions of people in the UK alone.

«It's an exciting development, and we await the outcome over the next year to see how well these cells integrate, and if there are any potential adverse reactions,» says Mike Cheetham of the Institute of Ophthalmology at University College London, one site where research is under way into a human embryonic stem - cell treatment for AMD.

Peter Coffey, a stem - cell biologist at the Institute of Ophthalmology in London, is developing an embryonic - stem - cell treatment for macular degeneration with the global drug company Pfizer.

Researchers are designing the first clinical trials of stem cell treatments for fetuses afflicted with rare bone and blood diseases.

It is anticipated that these results will be used for stem cell treatments for cutaneous disorders associated with various damage and lesions.

Stem cell treatments for chronic wounds could be more effective if patients simply took anti-inflammatory drugs during treatment.

Since 2011, though, experimental CAR T cell treatments for B cell leukemias and lymphomas — cancers in which patients» healthy B cells turn cancerous — have been successful in some patients for whom all standard therapies had failed.

Several clinics outside the U.S. also offer cord blood stem cell treatments for autism.

Tsukamoto says that if the therapy proves efficacious it could lead to neural stem cell treatments for multiple sclerosis, cerebral palsy, and Alzheimer's disease.

Despite this fact, several international clinics offer stem cell treatments for a variety of degenerative conditions, including glaucoma.

«CIRM was created to help develop stem cell treatments for diseases that are currently incurable with traditional approaches,» C. Randal Mills president and CEO of the stem cell agency, said in an agency statement.

There are no approved stem cell treatments for MS at this time, but there are various approaches being tested in clinical trials.

Vet - Stem is the first and only company so far to use fat - derived stem cell treatments for commercial use.

The Food and Drug Administration has launched a crackdown on clinics hawking stem cell treatments for a range of ailments.

Our mission is to accelerate stem cell treatments for patients with unmet medical needs by funding promising stem cell research in California.

Not exact matches

A Warren spokesman said later that Warren was referring to an April report by Politico that said separate legislation helping companies get approval for stem - cell treatments was backed by Ed Bosarge, a wealthy Texan.

The company has been trying to win FDA approval for Opdivo to be used as a first option treatment for non-small cell lung cancer (NSCLC).

In March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.

Also in San Diego, Ceregene is developing a treatment for decaying brain cells that works via an injection of a harmless virus infused with a protein that keeps such cells functional.

Gilead subsidiary Kite Pharma (which the biotech giant scooped up ahead of the FDA's approval for Yescarta, a treatment that reengineers patients» immune cells to fight cancer) will have access to Sangamo's platform technology, which could be used to create various types of cancer cell therapies.

About Nohla Therapeutics Nohla Therapeutics is a leading developer of off - the shelf cell therapies for the treatment of cancer and other critical diseases.

On Wednesday, the U.S. Food and Drug Administration approved Novartis» Kymriah, the first drug for a new kind of cancer treatment called CAR - T cell therapy.

Bellicum is among the flurry of biotechs investing heavily into cell therapies such as experimental chimeric antigen receptor T - cell (CAR - T) treatments for cancer (this is the next - gen treatment that involves reprogramming immune cells to become cancer killers and has shown promise in blood cancers, which Bellicum specializes in).

The new indication puts Kymriah in direct competition with Gilead Sciences» Yescarta, which was approved by the U.S. Food and Drug Administration in October for treatment of adults with diffuse large B - cell lymphoma who have failed to respond to other treatments.

It's the second approval for this pioneering approach to cancer treatment, which involves re-engineering patients» own immune cells to become cancer killers, after the FDA's approval of Novartis» Kymriah in August.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Researchers from Osaka University, in collaboration with the Max Planck Institute for Polymer Research, recently found a way to produce polymer solar cells without the need for these specialized treatments, while improving its conductivity, by using amorphous polymer blends and adding a component.

«We remain committed to developing better treatments for patients battling ALL and believe an approach using our defined cell technology is the best platform to pursue,» Bishop added.

Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR - V7 protein expression test using Epic Sciences» non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration - resistant prostate cancer.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

The concert benefits Summit for Stem Cell Foundation, a community initiative with patients, scientists and doctors to develop a Parkinson's treatment...

Merck already has an FDA approved immunotherapy drug with KEYTRUDA, a treatment for non-small cell lung cancer.

New treatments for everything from cancer to rare genetic diseases are entering the market all the time, many of which are cutting - edge biologic medicines derived from living cells.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmCell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmcell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmcell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

«This response rate is unprecedented for patients who had stopped responding to all other treatments,» says Michel Sadelain, a founding director of Memorial Sloan Kettering's Center for Cell Engineering and a cofounder of Juno.

You may not be for stem cell research, but what if there was a treatment that utilized stem cells (that would have been tossed away) that would curb a crippling disease tormenting your child or loved one?

The truth, of course, is that there are no human embryonic stem - cell therapies even in clinical trial, let alone ready for therapy, and there have been no major treatment....

As outlined in the previous Cutting Edge column (Jan / Feb 2014), 3D printing of cells offers impressive possibilities for medical treatments and research.

God started with a small party in a garden, moved on toward some pow - wows at alters in the desert, then moved into a moveable tabernacle (kind of like an Old Testament RV), then reigned in a temple (especially the God - cave of the Holy of Holies, then disappeared while giving the Jews the silent treatment for some 400 years, then came back to the temple, then traveled the highways and byways with anyone who wanted to join the fun and whooped it up with society's outcasts and wedding attenders, then moved on to some public forums, then into some clandestine home groups and a few jail cells, and eventually made his way into traditional church as we now know it.

research; since most of the reports have concentrated on justifying the creation of cloned human embryos for research into and treatment of neurodegenerative diseases such as Parkinson's, «stem - cells» has become synonymous with «embryonic stem - cells» in the public imagination.